Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

75.82
-6.0800-7.42%
Post-market: 75.820.00000.00%19:15 EDT
Volume:1.43M
Turnover:110.19M
Market Cap:5.18B
PE:-24.41
High:83.65
Open:81.00
Low:75.44
Close:81.90
52wk High:122.20
52wk Low:45.91
Shares:68.29M
Float Shares:55.48M
Volume Ratio:0.99
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-3.1100
ROE:-90.45%
ROA:-27.51%
PB:37.23
PE(LYR):-24.38

Loading ...

S&P 500 Futures Up In Premarket Trading; Jazz Pharmaceuticals, Clearwater Analytics Lead

Dow Jones
·
Nov 17, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Nov 11, 2025

Rhythm Pharmaceuticals Reports Setmelanotide Significantly Reduces BMI in Hypothalamic Obesity Phase 3 Trial

Reuters
·
Nov 10, 2025

Rhythm Pharmaceuticals price target raised to $114 from $105 at Canaccord

TIPRANKS
·
Nov 10, 2025

Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Eli Lilly & Co (LLY)

TIPRANKS
·
Nov 10, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Nov 08, 2025

Sector Update: Health Care Stocks Retreat Friday Afternoon

MT Newswires Live
·
Nov 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton Interactive

Reuters
·
Nov 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Wendy's, nLIGHT

Reuters
·
Nov 07, 2025

BUZZ-Rhythm falls after US FDA delays decision on drug for brain damage-related obesity

Reuters
·
Nov 07, 2025

Rhythm Pharmaceuticals Shares Down 3.5% Premarket After US FDA Extends Review of Co's Brain Damage-Related Obesity Drug

THOMSON REUTERS
·
Nov 07, 2025

FDA Extends Review of Rhythm Pharmaceuticals' IMCIVREE for Acquired Hypothalamic Obesity

Reuters
·
Nov 07, 2025

Rhythm Pharmaceuticals: FDA in Oct Requested Additional Sensitivity Analyses of Efficacy Data From Phase 3 Trial in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Nov 07, 2025

Rhythm Pharmaceuticals Inc: Major Amendment Did Not Include Any Information Relating to Safety or Manufacturing of Setmelanotide

THOMSON REUTERS
·
Nov 07, 2025

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for Imcivree® (Setmelanotide) for Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Nov 07, 2025

Rhythm Pharmaceuticals Inc: FDA Sets Updated Pdufa Goal Date of March 20, 2026

THOMSON REUTERS
·
Nov 07, 2025

Rhythm Pharmaceuticals Inc - Announces Listing Agreements in Five Canadian Provinces

THOMSON REUTERS
·
Nov 06, 2025

Rhythm Pharmaceuticals Announces Public Reimbursement for Imcivree® (Setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

THOMSON REUTERS
·
Nov 06, 2025

Rhythm Pharmaceuticals Secures Public Reimbursement for IMCIVREE in Five Canadian Provinces and Under NIHB Program

Reuters
·
Nov 06, 2025

Stock Track | Rhythm Pharmaceuticals Plummets 5.65% Following Oppenheimer Downgrade

Stock Track
·
Nov 05, 2025